The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury
Open accessAbstract
Background: Traumatic brain injury (TBI) with its associated morbidity is a major area of unmet medical need that lacks effective therapies. TBI initiates a neuroinflammatory cascade characterized by activation of astrocytes and microglia, and increased production of immune mediators including proinflammatory cytokines and chemokines. This inflammatory response contributes both to the acute pathologic processes following TBI including cerebral edema, in addition to longer-term neuronal damage and cognitive impairment. However, activated glia also play a neuroprotective and reparative role in recovery from injury. Thus, potential therapeutic strategies targeting the neuroinflammatory cascade must use careful dosing considerations, such as amount of drug and timing of administration post injury, in order not to interfere with the reparative contribution of activated glia. Methods: We tested the hypothesis that attenuation of the acute increase in proinflammatory cytokines and chemokines following TBI would decrease neurologic injury and improve functional neurologic outcome. We used the small molecule experimental therapeutic, Minozac (Mzc), to suppress TBI-induced up-regulation of glial activation and proinflammatory cytokines back towards basal levels. Mzc was administered in a clinically relevant time window post-injury in a murine closed-skull, cortical impact model of TBI. Mzc effects on the acute increase in brain cytokine and chemokine levels were measured as well as the effect on neuronal injury and neurobehavioral function. Results: Administration of Mzc (5 mg/kg) at 3 h and 9 h post-TBI attenuates the acute increase in proinflammatory cytokine and chemokine levels, reduces astrocyte activation, and the longer term neurologic injury, and neurobehavioral deficits measured by Y maze performance over a 28-day recovery period. Mzc-treated animals also have no significant increase in brain water content (edema), a major cause of the neurologic morbidity associated with TBI. Conclusion: These results support the hypothesis that proinflammatory cytokines contribute to a glial activation cycle that produces neuronal dysfunction or injury following TBI. The improvement in long-term functional neurologic outcome following suppression of cytokine upregulation in a clinically relevant therapeutic window indicates that selective targeting of neuroinflammation may lead to novel therapies for the major neurologic morbidities resulting from head injury, and indicates the potential of Mzc as a future therapeutic for TBI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“The causes of TBI vary with age but the medical and financial impact of these injuries is substantial [4,5].”
BackgroundAntiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Incidence of mild and moderate brain injury in the United States, 1991
D. M. SOSIN, J. E. S. (1996) · Brain Injury · doi:10.1080/026990596124719 · Cited by 594
Munoz, L., Ranaivo, H. R., Roy, S. M., Hu, W., Craft, J. M., McNamara, L. K., Chico, L. W., Van Eldik, L. J., & Watterson, D. M. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-21 · Cited by 224
Self-citationLynch, J. R., Pineda, J. A., Morgan, D., Zhang, L., Warner, D. S., Benveniste, H., & Laskowitz, D. T. (2002) · Annals of Neurology · doi:10.1002/ana.10098 · Cited by 111
Cited by
The role of inflammation in epilepsy
Vezzani, A., French, J., Bartfai, T., & Baram, T. Z. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.178 · Cited by 1,876
Microglial Activation in Traumatic Brain Injury
Donat, C. K., Scott, G., Gentleman, S. M., & Sastre, M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00208 · Cited by 480
Modulation of immune response by head injury
Morganti-Kossmann, M. C., Satgunaseelan, L., Bye, N., & Kossmann, T. (2007) · Injury · doi:10.1016/j.injury.2007.10.005 · Cited by 412
Neuroinflammation in the normal aging hippocampus
Barrientos, R. M., Kitt, M. M., Watkins, L. R., & Maier, S. F. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.03.007 · Cited by 315
Targeting protein kinases in central nervous system disorders
Chico, L. K., Van Eldik, L. J., & Watterson, D. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2999 · Cited by 298
Self-citation
Metadata
- Authors
- Lloyd, E., Somera-Molina, K., Van Eldik, L. J., Watterson, D. M., & Wainwright, M. S.
- Venue
- Journal of Neuroinflammation
- Published
- 2008-06-30
- Volume
- 5
- Issue
- 1
- Pages
- 28-28
- ISSN
- 1742-2094 (ISSN-L)
- OpenAlex
- W2010527958
- Cited by
- 180
- References
- 5
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. https://app.cochat.ai/papers/10.1186/1742-2094-5-28
- The paper
- Lloyd, E., Somera-Molina, K., Van Eldik, L. J., Watterson, D. M., & Wainwright, M. S. (2008). Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. Journal of Neuroinflammation. https://doi.org/10.1186/1742-2094-5-28
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.